M Dominguez-Valentin

List of Publications by Year
in descending order

60	2,120	279798	243625
papers	citations	23 h-index	44 g-index

64	64	64	3381
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	First international workshop of the ATM and cancer risk group (4-5 December 2019). Familial Cancer, 2022, 21, 211-227.	1.9	10
2	Patterns of germline and somatic testing after universal tumor screening for Lynch syndrome: A clinical practice survey of active members of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Journal of Genetic Counseling, 2022, 31, 949-955.	1.6	4
3	Response to Chambuso etÂal. Genetics in Medicine, 2022, , .	2.4	0
4	Prospective observational data informs understanding and future management of Lynch syndrome: insights from the Prospective Lynch Syndrome Database (PLSD). Familial Cancer, 2021, 20, 35-39.	1.9	19
5	Letter to the Editor-Recent advances in Lynch syndrome. Familial Cancer, 2021, 20, 117-118.	1.9	1
6	Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum. International Journal of Cancer, 2021, 148, 512-513.	5.1	9
7	The â€œunnaturalâ€•history of colorectal cancer in Lynch syndrome: Lessons from colonoscopy surveillance. International Journal of Cancer, 2021, 148, 800-811.	5.1	55
8	Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Genetics in Medicine, 2021, 23, 705-712.	2.4	28
9	European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. British Journal of Surgery, 2021, 108, 484-498.	0.3	130
10	Challenges to Bringing Personalized Medicine to a Low-Resource Setting in Peru. International Journal of Environmental Research and Public Health, 2021, 18, 1470.	2.6	2
11	Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. European Journal of Cancer, 2021, 148, 124-133.	2.8	11
12	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. Journal of Clinical Medicine, 2021, 10, 2856.	2.4	11
13	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncology, The, 2021, 22, 1014-1022.	10.7	58
14	Towards evidence-based personalised precision medicine for Lynch syndrome. Lancet Oncology, The, 2021, 22, e383.	10.7	0
15	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genetics in Medicine, 2020, 22, 15-25.	2.4	365
16	Response to Tolva et al.. Genetics in Medicine, 2020, 22, 813-814.	2.4	0
17	ActualizaciÃ³n en cÃ¡ncer colorrectal hereditario y su impacto en salud pÃºblica. Revista Facultad De Medicina, 2020, 68, .	0.2	0
18	Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database. Journal of Clinical Medicine, 2020, 9, 2290.	2.4	12

#	Article	IF	Citations
19	MLH1 intronic variants mapping toâ€‰+â€‰5 position of splice donor sites lead to deleterious effects on RNA splicing. Familial Cancer, 2020, 19, 323-336.	1.9	5
20	Spectrum and Frequency of Tumors, Cancer Risk and Survival in Chilean Families with Lynch Syndrome: Experience of the Implementation of a Registry. Journal of Clinical Medicine, 2020, 9, 1861.	2.4	1
21	Prevalence of theBRAFp.v600e variant in patients with colorectal cancer from Mexico and its estimated frequency in Latin American and Caribbean populations. Journal of Investigative Medicine, 2020, 68, 985-991.	1.6	8
22	A snapshot of current genetic testing practice in Lynch syndrome: The results of a representative survey of 33 Latin American existing centres/registries. European Journal of Cancer, 2019, 119, 112-121.	2.8	13
23	Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 28.	1.5	27
24	Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 8.	1.5	42
25	Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift. Cancers, 2019, 11, 132.	3.7	7
26	Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing. Scientific Reports, 2019, 9, 18555.	3.3	13
27	From colorectal cancer pattern to the characterization of individuals at risk: Picture for genetic research in Latin America. International Journal of Cancer, 2019, 145, 318-326.	5.1	14
28	Evaluation of MLH1 variants of unclear significance. Genes Chromosomes and Cancer, 2018, 57, 350-358.	2.8	10
29	Mitochondrial mutations associated with hearing and balance disorders. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2018, 810, 39-44.	1.0	3
30	Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families. Familial Cancer, 2018, 17, 141-153.	1.9	12
31	Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 2018, 67, 1306-1316.	12.1	410
32	Universal determination of microsatellite instability using BAT26 as a single marker in an Argentine colorectal cancer cohort. Familial Cancer, 2018, 17, 395-402.	1.9	5
33	Identification of genetic variants for clinical management of familial colorectal tumors. BMC Medical Genetics, 2018, 19, 26.	2.1	18
34	Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds. Hereditary Cancer in Clinical Practice, 2018, 16, 4.	1.5	7
35	Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients. OncoImmunology, 2017, 6, e1336272.	4.6	17
36	A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America. BMC Cancer, 2017, 17, 623.	2.6	40

#	Article	IF	Citations
37	MLH1 Ile219Val Polymorphism in Argentinean Families with Suspected Lynch Syndrome. Frontiers in Oncology, 2016, 6, 189.	2.8	4
38	Lynch syndrome in South America: past, present and future. Familial Cancer, 2016, 15, 437-445.	1.9	6
39	Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urology, 2016, 16, 15.	1.4	52
40	Identification of a Natural Killer Cell Receptor Allele That Prolongs Survival of Cytomegalovirus-Positive Glioblastoma Patients. Cancer Research, 2016, 76, 5326-5336.	0.9	26
41	Update on Hereditary Colorectal Cancer. Anticancer Research, 2016, 36, 4399-4406.	1.1	60
42	Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. Urology, 2015, 86, 1212-1217.	1.0	74
43	Familial colorectal cancer type X: genetic profiles and phenotypic features. Modern Pathology, 2015, 28, 30-36.	5.5	37
44	Functional implications of the p.Cys680Arg mutation in the MLH1 mismatch repair protein. Molecular Genetics & Genomic Medicine, 2014, 2, 352-355.	1.2	1
45	Key Roles for MYC, KIT and RET signaling in secondary angiosarcomas. British Journal of Cancer, 2014, 111, 407-412.	6.4	28
46	Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome. Familial Cancer, 2014, 13, 537-545.	1.9	13
47	Molecular Subtyping of Serous Ovarian Tumors Reveals Multiple Connections to Intrinsic Breast Cancer Subtypes. PLoS ONE, 2014, 9, e107643.	2.5	17
48	Gain of chromosomal region 20q and loss of 18 discriminates between Lynch syndrome and familial colorectal cancer. European Journal of Cancer, 2013, 49, 1226-1235.	2.8	23
49	Mutation spectrum in South American Lynch syndrome families. Hereditary Cancer in Clinical Practice, 2013, 11, 18.	1.5	26
50	Distinct Gene Expression Signatures in Lynch Syndrome and Familial Colorectal Cancer Type X. PLoS ONE, 2013, 8, e71755.	2.5	28
51	Abstract B8: Molecular subtyping of epithelial ovarian cancer reveals connections to intrinsic breast cancer subtypes. , 2013, , .		0
52	Functional characterization ofMLH1missense variants identified in lynch syndrome patients. Human Mutation, 2012, 33, 1647-1655.	2.5	21
53	Molecular insights on basal-like breast cancer. Breast Cancer Research and Treatment, 2012, 134, 21-30.	2.5	73
54	Predictive models for mutations in mismatch repair genes: implication for genetic counseling in developing countries. BMC Cancer, 2012, 12, 64.	2.6	11

#	Article	IF	Citations
55	Advances and applications of oral cancer basic research. Oral Oncology, 2011, 47, 783-791.	1.5	116
56	Characterization of germline mutations of MLH1 and MSH2 in unrelated south American suspected Lynch syndrome individuals. Familial Cancer, 2011, 10, 641-647.	1.9	25
57	Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry. Familial Cancer, 2010, 9, 563-570.	1.9	37
58	Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors. Sao Paulo Medical Journal, 2009, 127, 288-294.	0.9	6
59	Mismatch repair genes in Lynch syndrome: a review. Sao Paulo Medical Journal, 2009, 127, 46-51.	0.9	56
60	Two new MLH1 germline mutations in Brazilian lynch syndrome families. International Journal of Colorectal Disease, 2008, 23, 1263-1264.	2.2	3